Better treatments for HCV are promising a cure in many if not most HCV cases over the next 10 years.
Outcomes will improve because graft survival improves when the graft isn't infected with HCV (e.g. http://www.ncbi.nlm.nih.gov/pubmed/15996238), and treatment pre- or post-transplant will be much better tolerated with interferon-free therapy. These benefits should be at least as apparent in HIV/HCV co-infected individuals. Whether additional sites engage with this population is multifactorial, but improved outcomes (and treatment options) can only help.
Patients HIV / HCVco-infected have a good chance due to the DAA, they have shown a sustained virologic response better than the standard treatment in this population
I certainly expect the outcomes for the HIV/HCV co-infected patients to improve for liver transplantation if treated early or before transplant to reduce the exaggerated impact of HCV recurrence on survival. This is what happened with HBV in LTX and the survival of HBV/HIV co-infected patients is excellent. Hopefully 10-15 years from now, there will not be any ESLD due to HCV, but that is a dream.
- Badges
- Science topic
- Similar topics
- Medicine
- Epi
- Age Groups
- Children